Bladder Cancer

Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates.

There is significant interest in identifying complete responders to neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) to potentially avoid removal of a pathologically benign bladder. However, clinical restaging after NAC is highly inaccurate.

Prognostic significance of EGFR, AREG and EREG amplification and gene expression in muscle invasive bladder cancer.

Muscle invasive bladder cancer (MIBC) remains a prevalent cancer with limited therapeutic options, obviating the need for innovative therapies. The epidermal growth factor receptor (EGFR) is a linchpin in tumor progression and presents a potential therapeutic target in MIBC.

UroGen Surges on Updated Late-Stage Data for Bladder Cancer Therapy

Reno, Nevada (UroToday.com) -- UroGen Pharma (NASDAQ:URGN) announced Thursday that its Phase 3 ENVISION trial for bladder cancer therapy UGN-102 (mitomycin), which had previously reached the primary endpoint, indicated a nearly 82% duration of response at 12 months.

A Tool for Evaluating Artificial Intelligence Studies for Predicting NMIBC Outcomes - Expert Commentary

Artificial intelligence (AI) models are emerging are powerful tools for the diagnosis and risk stratification of several cancers but have not been widely adopted in clinical practice. To evaluate barriers to AI integration and facilitate evaluation of new models for clinical adoption in the context of non-muscle invasive bladder cancer (NMIBC), Kwong et al. developed APPRAISE-AI, a quantitative tool for assessing the quality of AI studies in this field.

Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multi-Site Single-Institution Prospective Study.

This study aimed to investigate the prevalence of pathogenic germline variants (PGV) in hereditary cancer genes utilizing a universal testing approach and to determine the rate of PGV that would have been missed based on National Comprehensive Cancer Network (NCCN) guidelines in genitourinary (GU) malignancies.

An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer.

BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) represent a significant therapeutic challenge in the treatment of bladder cancer. Nadofaragene firadenovec, represents a breakthrough in this area, offering a novel approach for the treatment of BCG-unresponsive NMIBC.

Avelumab maintenance therapy for node-positive muscle invasive bladder cancer: a report of two cases.

Muscle-invasive bladder cancer (MIBC) with nodal involvement is associated with poor prognosis and high mortality. Treatment of node-positive MIBC is complex due to disease heterogeneity and a lack of evidence-based treatment options, especially alternatives to radical cystectomy.

ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol.

Transurethral resection of bladder tumour (TURBT) is one of the more common procedures performed by urologists. It is often described as an 'incision-free' and 'well-tolerated' operation. However, many patients experience distress and discomfort with the procedure.

Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

Cretostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate in cancer cells with retinoblastoma pathway alterations, previously tested as monotherapy in bacillus Calmette-Guérin (BCG)-experienced non-muscle-invasive bladder cancer.

Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment.

Due to bladder tumors' contact with urine, urine-derived cells (UDCs) may serve as a surrogate for monitoring the tumor microenvironment (TME) in bladder cancer (BC). However, the composition of UDCs and the extent to which they mirror the tumor remain poorly characterized.